相似文献
1
Asthma and COVID-19: What do we know now.哮喘与2019冠状病毒病：我们目前了解到什么
Clin Med Insights Circ Respir Pulm Med. 2020 Oct 23;14:1179548420966242. doi: 10.1177/1179548420966242. eCollection 2020.
2
COVID-19, asthma, and biological therapies: What we need to know.新型冠状病毒肺炎、哮喘与生物疗法：我们需要了解的内容。
World Allergy Organ J. 2020 May 16;13(5):100126. doi: 10.1016/j.waojou.2020.100126. eCollection 2020 May.
3
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.COVID-19 风险和结局在接受生物制剂或全身皮质类固醇治疗的成年哮喘患者中的：全国真实世界证据。
J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15.
4
SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.严重哮喘患者接受生物制剂治疗后感染 SARS-CoV-2。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2588-2595. doi: 10.1016/j.jaip.2022.05.041. Epub 2022 Jun 23.
5
Asthma in the era of SARS CoV-2 virus.新冠病毒时代的哮喘
J Asthma. 2022 Aug;59(8):1501-1508. doi: 10.1080/02770903.2021.1941093. Epub 2021 Jun 21.
6
Asthma and severe acute respiratory syndrome coronavirus 2019: current evidence and knowledge gaps.哮喘与 2019 年严重急性呼吸综合征冠状病毒：现有证据与知识缺口。
Curr Opin Pulm Med. 2021 Jan;27(1):45-53. doi: 10.1097/MCP.0000000000000744.
7
Treatment of COVID-19-exacerbated asthma: should systemic corticosteroids be used?COVID-19 加重哮喘的治疗：是否应使用全身皮质类固醇？
Am J Physiol Lung Cell Mol Physiol. 2020 Jun 1;318(6):L1244-L1247. doi: 10.1152/ajplung.00144.2020. Epub 2020 May 13.
8
Severe asthma in the era of COVID-19: A narrative review.COVID-19 时代的严重哮喘：叙事性综述。
Pulmonology. 2022 Jan-Feb;28(1):34-43. doi: 10.1016/j.pulmoe.2021.04.001. Epub 2021 Apr 30.
9
[Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].[氯化乙酰甲胆碱支气管激发试验标准技术规范（2023年）]
Zhonghua Jie He He Hu Xi Za Zhi. 2024 Feb 12;47(2):101-119. doi: 10.3760/cma.j.cn112147-20231019-00247.
10
The SARS-CoV-2 pandemic and asthma: What we have learned and what is still unknown.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）大流行与哮喘：我们所了解的情况及仍未知的方面。
J Allergy Clin Immunol. 2023 Dec;152(6):1376-1381. doi: 10.1016/j.jaci.2023.09.005. Epub 2023 Sep 20.
引用本文的文献
1
Genomic analysis of severe COVID-19 considering or not asthma comorbidity: GWAS insights from the BQC19 cohort.考虑或不考虑哮喘合并症的严重 COVID-19 的基因组分析：来自 BQC19 队列的 GWAS 见解。
BMC Genomics. 2024 May 16;25(1):482. doi: 10.1186/s12864-024-10342-x.
2
Co-infection associated with SARS-CoV-2 and their management.与严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）相关的合并感染及其管理。
Future Sci OA. 2023 Feb 3;8(9):FSO819. doi: 10.2144/fsoa-2022-0011. eCollection 2022 Oct.
3
Frequent occurrence of mutations in nsp3 and nsp4 of SARS-CoV-2, presumably caused by the inhaled asthma drug ciclesonide.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的非结构蛋白3（nsp3）和非结构蛋白4（nsp4）频繁发生突变，推测是由吸入性哮喘药物环索奈德引起的。
PNAS Nexus. 2022 Sep 20;1(4):pgac197. doi: 10.1093/pnasnexus/pgac197. eCollection 2022 Sep.
4
Omalizumab may protect allergic patients against COVID-19: A systematic review.奥马珠单抗可能保护过敏患者预防新型冠状病毒肺炎：一项系统评价。
World Allergy Organ J. 2023 Feb;16(2):100741. doi: 10.1016/j.waojou.2023.100741. Epub 2023 Jan 9.
5
The Incidence and Severity of COVID-19 in the Liverpool Severe Asthma Population Undergoing Biologic Therapy.接受生物治疗的利物浦重症哮喘患者中新冠病毒病的发病率和严重程度
Cureus. 2022 Sep 5;14(9):e28790. doi: 10.7759/cureus.28790. eCollection 2022 Sep.
6
COVID-19 Phenotypes and Comorbidity: A Data-Driven, Pattern Recognition Approach Using National Representative Data from the United States.COVID-19 表型和合并症：一种使用来自美国的全国代表性数据进行数据驱动、模式识别的方法。
Int J Environ Res Public Health. 2022 Apr 12;19(8):4630. doi: 10.3390/ijerph19084630.
7
Case Report: Self-Administration of Omalizumab in an Adolescent With Severe Asthma During SARS-CoV-2 Infection.病例报告：一名重度哮喘青少年在感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）期间自行使用奥马珠单抗。
Front Pediatr. 2021 Dec 6;9:675281. doi: 10.3389/fped.2021.675281. eCollection 2021.
8
Delayed positive COVID19 nasopharyngeal test, a case study with clinical and pathological correlation.延迟的新冠病毒鼻咽拭子检测阳性，附临床与病理相关性病例研究。
BMC Pulm Med. 2021 Aug 31;21(1):278. doi: 10.1186/s12890-021-01643-y.
9
Covid-19 and non-communicable diseases: evidence from a systematic literature review.Covid-19 和非传染性疾病：系统文献回顾的证据。
BMC Public Health. 2021 Jun 5;21(1):1068. doi: 10.1186/s12889-021-11116-w.
10
Severe asthma in the era of COVID-19: A narrative review.COVID-19 时代的严重哮喘：叙事性综述。
Pulmonology. 2022 Jan-Feb;28(1):34-43. doi: 10.1016/j.pulmoe.2021.04.001. Epub 2021 Apr 30.
本文引用的文献
1
Montelukast in hospitalized patients diagnosed with COVID-19.孟鲁司特钠在 COVID-19 住院患者中的应用。
J Asthma. 2022 Apr;59(4):780-786. doi: 10.1080/02770903.2021.1881967. Epub 2021 Mar 4.
2
Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis.基础合并症对 COVID-19 患者死亡发生的影响：系统评价和荟萃分析。
J Glob Health. 2020 Dec;10(2):020503. doi: 10.7189/jogh.10.020503.
3
The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells.吸入性类固醇 Ciclesonide 通过靶向细胞培养中的病毒复制转录复合物来阻断 SARS-CoV-2 RNA 复制。
J Virol. 2020 Dec 9;95(1). doi: 10.1128/JVI.01648-20.
4
Type 2 and interferon inflammation regulate SARS-CoV-2 entry factor expression in the airway epithelium.2 型糖尿病和干扰素炎症调节气道上皮细胞中的 SARS-CoV-2 进入因子表达。
Nat Commun. 2020 Oct 12;11(1):5139. doi: 10.1038/s41467-020-18781-2.
5
Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights.COVID-19 爆发期间肺功能检查的实用考虑：文献回顾与见解。
Pulmonology. 2021 Sep-Oct;27(5):438-447. doi: 10.1016/j.pulmoe.2020.07.011. Epub 2020 Aug 5.
6
PROMOTING SAFE AND EFFECTIVE USE OF AEROSOL DEVICES IN COVID-19:RISKS AND SUGGESTIONS FOR VIRAL TRANSMISSION.促进新冠疫情期间气溶胶装置的安全有效使用：病毒传播风险与建议
Expert Opin Drug Deliv. 2020 Nov;17(11):1509-1513. doi: 10.1080/17425247.2020.1811225. Epub 2020 Sep 10.
7
SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation.住院哮喘患者的 SARS-CoV-2 肺炎并未引发严重恶化。
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2600-2607. doi: 10.1016/j.jaip.2020.06.032. Epub 2020 Jun 27.
8
Work Group Report: COVID-19: Unmasking Telemedicine.工作组报告：COVID-19：揭开远程医疗的面纱。
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2461-2473.e3. doi: 10.1016/j.jaip.2020.06.038. Epub 2020 Jun 27.
9
Montelukast's ability to fight COVID-19 infection.孟鲁司特抗击新冠病毒感染的能力。
J Asthma. 2021 Oct;58(10):1348-1349. doi: 10.1080/02770903.2020.1786112. Epub 2020 Sep 17.
10
Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19.COVID-19 住院和非住院患者中哮喘的患病率和特征。
J Allergy Clin Immunol. 2020 Aug;146(2):307-314.e4. doi: 10.1016/j.jaci.2020.06.010. Epub 2020 Jun 15.
Zotero 插件